| 16.28 -1.02 (-5.9%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 21.4  |
1-year : | 22.99 |
| Resists | First : | 18.33 |
Second : | 19.69 |
| Pivot price | 17.92 |
|||
| Supports | First : | 16.12 |
Second : | 13.42 |
| MAs | MA(5) : | 17.19 |
MA(20) : | 17.98 |
| MA(100) : | 18.15  |
MA(250) : | 13.05 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 9.3 |
D(3) : | 15.3 |
| RSI | RSI(14): 35.2 |
|||
| 52-week | High : | 21.27 | Low : | 5.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RLAY ] has closed below the lower bollinger band by 3.5%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 3.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.29 - 17.37 | 17.37 - 17.45 |
| Low: | 15.89 - 15.99 | 15.99 - 16.09 |
| Close: | 16.09 - 16.25 | 16.25 - 16.41 |
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Fri, 16 Oct 2026
Relay: The Recent Market Excitement Ignores The Reality Of Clinical Risks And Patent Cliffs - Seeking Alpha
Thu, 15 Oct 2026
H.C. Wainwright raises target for Relay Therapeutics stock to USD 29 - ad-hoc-news.de
Tue, 13 Oct 2026
Analysts Are Bullish on Top Healthcare Stocks: Alvotech (ALVO), Relay Therapeutics (RLAY) - The Globe and Mail
Thu, 08 Oct 2026
Relay Therapeutics Insider Sold Shares Worth $329,322, According to a Recent SEC Filing - Yahoo Finance
Thu, 08 Oct 2026
CEO sells 48,199 shares under a trading plan at Relay Therapeutics (RLAY). - Stock Titan
Thu, 08 Oct 2026
Under a trading plan, Relay Therapeutics (RLAY) CFO sells 17,511 shares plus 206 more. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 219 (M) |
| Held by Insiders | 1.4548e+008 (%) |
| Held by Institutions | 1.5 (%) |
| Shares Short | 43,550 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.0822e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -25 % |
| Return on Assets (ttm) | 949.7 % |
| Return on Equity (ttm) | -22.9 % |
| Qtrly Rev. Growth | 1.035e+007 % |
| Gross Profit (p.s.) | -27.92 |
| Sales Per Share | -21.26 |
| EBITDA (p.s.) | -1.49422e+008 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -212 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.77 |
| Price to Cash Flow | 6.92 |
| Dividend | 0 |
| Forward Dividend | 4.675e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|